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ABSTRACT
Objective: Chemokine (C-C motif) ligand 2 (CCL2), a candidate of cytokines, orchestrates immune cell recruitment to inflamed organs. CCL2 has been 
shown to have direct angiogenic effects, so providing an anti-angiogenic agent, Avastin (AV), to be combined with the CCR2 antagonist (concentration ratio 
[CR]) plays an essential role in the hemostatic strategy for immunomodulation. Lack of targetability and the adverse effects of chemical treatments are the 
main obstacles led scientists to develop novel strategies using nano-delivery approaches such as pegylated nanoparticles (NPs) which exhibits reduced 
drug clearance rates. The rationale of the current study is to test the in vivo immunomodulatory effects of AV and/or CR in their NPs or free counterparts.
Methods: These NPs were synthesized and characterized using different physicochemical techniques. Males Wistar rats (n=114) were used and 
divided into 7 groups treated with vehicle, AV, AVNP, CCR2 antagonist (CR), CCR2 antagonist NPs (CRNP), AV-CCR2 antagonist (AVCR), and AV-CCR2 
antagonist NPs (AVCRNP). Groups were subdivided into three subgroups according to the administrated dose. Blood was taken from rats for differential 
leukocyte and platelet profile measurements. Sera were collected to test vascular endothelial growth factor (VEGF) levels. Autopsy samples from liver 
were taken for histopathological investigation.
Results: The morphology of the NPs was spherical and had sizes ranging from 89.89 nm to 146 nm. Monocytes and lymphocytes accumulated in the 
blood circulation and VEGF levels were inhibited after AV and CR administrations. In addition, large platelets concentration ratio was elevated in the 
blood circulation.
Conclusion: We concluded that AV ad CR therapeutic regimens have an immunomodulatory role through induction of monocyte-platelet aggregation 
and inhibition of VEGF.
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INTRODUCTION
Chemokine (C-C motif) ligand 2 (CCL2) is a candidate of a cytokines 
group called “chemokines.” CCL2 has a chemoattractant potential 
and arranges immune cell staffing to precise organs. Its expression 
is mandatory for homeostatic purposes such as adapting immune 
cell transferring from blood circulation to an inflamed organ [1]. The 
expression of CCL2 is found in an extensive range of cells including 
myeloid, fibroblasts, etc. Importantly, CCL2 binds its receptor CCR2 
and acts as a potent chemoattractant for monocytes, lymphocytes, and 
basophils infiltration from blood to an organ [2].
CCL2 was primarily branded as a monocyte chemotactic protein 1 (MCP-1), 
and it was considered as one of MCPs family. This family is essential to 
prompt signal transduction pathways and exerts biological functions such 
as chemotaxis [3].
CCL2 differently binds its receptor (CCR2), which is expressed in 
several areas such as blood, kidney, and liver. There are two isoforms 
of the expressed CCR2 due to splicing process of CCR2A and CCR2B [4].
Apart from CCR2, the ligand (CCL2) may bind other MCP receptors 
as well. CCL2 was found to bind other receptors such as CCR4 on 
lymphocytes, resulting in their staffing to melanoma cells, thereafter 
involving an immune-relevant protective effect against tumor [5]. 
This recruitment flexibility leads to different biological consequences, 
depending on the connection between chemokine and its receptor [6]. 
For instance, binding of CCL7/2 with CCR2 may inspire monocyte 
expatriation from the bone marrow to the site of interest [7]. Similarly, 
binding CCL8/2 with CCR2 on colorectal cancerous cells may incite a 
comparable induction in angiogenesis and metastasis [8]. Considering 
the explicit immunomodulatory effects of CCL2-CCR2 signaling is an 
inspiring aspect. However, the link between CCL2 and CCR2 appears 
to be a ubiquitous connection with silenced CCL2, resulting in similar 
phenotypes of those deficient in CCR2 [9,10].
Monocytes, a group of leukocytes that articulates chemokine-related 
receptors, are originally produced in the bone marrow and are 
unconstrained into the blood circulation [11]. The CCL2 receptor (CCR2) 
is found on monocytes that are related with immune protection against 
inflammation [12].
CCL2-CCR2 signal defends prostate cancer cells through induction of 
programmed death by PI3K/Akt/survivin path [13]. In addition to 
effects on tumor cells, CCL2 also intervenes stromal cell replies in the 
prostate cancer environment. CCL2 blockade using a specific antibody 
in in vivo model suppressed tumor development, reduced macrophage 
permeation, and led to compact tumor-related vasculature [14]. 
Although CCL2 was exposed to have angiogenic effects in many reports, 
another story proved that it stimulated cancer cells to upregulate the 
vascular endothelial growth factor (VEGF) expression as an angiogenic 
factor [15]. Thus, providing an anti-VEGF agent, like Avastin (AV), to 
be combined with the CCR2 antagonist in the current study gaining 
a hemostatic strategy for an in vivo immunomodulation. Anti-VEGF 
therapy reduced vessel size and tortuosity with more pericyte coverage 
of the remaining normalized vessels [16].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i1.29337
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Lack of targetability and instability in addition to adverse effects 
of chemical-based treatments are the main obstacles led scientists 
to develop novel strategies to tackle diseases using nano-delivery 
approaches [17-21]. Recently, several delivery systems were 
developed by utilizing pegylated products [22]. These procedures 
augmented the half-life and bustle of drugs, and diminished liver 
toxicity [23].
Overall, the rationale of the current study is to test the immunom 
odulatory effects of the anti-VEGF AV and/or CCR2 antagonist (CR) in 
their pegylated nanoformulation or free counterparts, understanding 
the mechanisms modulating immunity in rats to get closer to suggest 
some further recommendations regarding angiogenesis-mediated 
immunomodulation through targeting liver microenvironment which 
may gain great success in cancer eradication in near future.
MATERIALS AND METHODS
Materials
Methoxy polyethylene glycol amine (mPEG-NH2, MW 5000 Da), 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide (NHS), 
heparin (HP), PEG (MW 5000 Da), 2-(N morpholine) ethanesulfonic acid 
(MES), dimethyl sulfoxide, Tween 80, and poly L-lysine (PLL), and CCR2 
antagonist RS 504393 (CR) were purchased from Sigma-Aldrich, USA. 
Bevacizumab AV was purchased from Genentech Inc., USA. Ultrapure 
water (Millipore, Bedford, MA, USA) was used.
Preparation of AV and CR nanoparticles (NPs)
Nano-void (NV) synthesis
According to a previous method mentioned in Lim et al. [24], we used 
it with some modifications to prepare PEG-exposed NPs (NV). To 
prepare NV, we first prepared the mixture of EDC and NHS. Briefly, HP 
(HP: 0.1 mMol) was coupled with 0.1 mM of mPEG-NH2 (MW 5000 Da) 
using EDC (1.5 mMol) and NHS (1.6 mMol) in MES buffer (0.1 M, pH 5.5) 
at room temperature for 24 h stirring. Then, NV was prepared simply by 
mixing the polymer (PEG-HP) with PPL buffer (6:1 v/v ratio) overnight 
at 4°C.
AVNPs synthesis
To prepare the PEG-NPs of bevacizumab AV monoclonal antibody 
(AV NPs); first, the PEG-HP polymer was synthesized as above and 
the core NPs were prepared by mixing the polymer with PLL buffer 
overnight at 4°C using this ratio (1:6 v/v, PLL: PEG-HP). Then, AV NPs 
were synthesized by activating the amine groups in the formed NPs 
mixture using EDC and NHS to bind with the carboxylic groups in 
25 mg/mL monoclonal antibody (AV) by stirring overnight at 4°C, after 
that amide bonds were formed and the AVNPs were functionalized.
CCR2 antagonist NPs synthesis
To prepare the PEG-NPs of CCR2 antagonist RS 504393 (CRNPs), simply 
the PEG-HP polymer was synthesized as above, and the CRNPs were 
prepared by mixing the polymer with PLL buffer overnight at 4°C 
using this ratio (1: 6 v/v, PLL: PEG-HP). Before adding PLL to form 
the CR NPs, 2 mg/mL CCR2 antagonist RS 504393 of CR was titrated 
to the PEG/HP polymer. This mixture was vortexed for 5 min and 
subsequently sonicated for 5 min using a Sonics Vibra-cell sonifier 
VC750 equipped with a micro-tip (Newtown, CT) at amplitude = 35%, 
pulse-on = 5.0 s, and pulse-off = 3.0 s. The suspension was transferred 
to a round-bottom tube in a water bath with magnetic stirring overnight 
at room temperature.
AV-CR NPs synthesis
To prepare AV-CRNPs, first, the CRNPs were synthesized as a core 
vehicle (as mentioned above) then the amine groups were activated 
using EDC and NHS to bind the carboxylic groups in 25 mg/mL 
monoclonal antibody (AV) by stirring overnight at 4°C, after that amide 
bonds were formed, and the AV-CRNPs were functionalized.
NPs characterization
Dialysis technique and measurement of the encapsulation 
efficiency
All nano-samples were divided into two portions; (1) one for measuring 
the total concentrations of the free plus nano-conjugated AV and 
CR and (2) the second part for measuring the concentrations of the 
nano-conjugated AV and CR after performing dialysis tubing technique 
for eliminating the impurities and the free drug using a membrane 
bag (Spectra/Por Membrane, Spectrum Laboratories, USA; molecular 
weight cut-off, MWCO: 25,000 Da).
The free and conjugated forms of AV and CCR2 antagonist were detected 
with a variable wavelength detector using a UV-based ELISA system. 
The calibration curves for quantification of these compounds were 
linear over the range of standard concentrations. Finally, encapsulating 
(entrapment) efficiency (EE) was calculated after dialysis technology.
Transmission electron microscopic (TEM)
Particle morphology of all NPs was examined by TEM (TEM, Philips 
CM-10, FEI Inc., Hillsboro, OR, USA). 100 µg/ml of the nano-suspensions 
were dropped into formvar-coated copper grids, and after complete 
drying, the samples were stained using 2% w/v Uranyl Acetate (Electron 
Microscopy Services, Ft. Washington, PA). Image capture and analysis 
were done using Digital Micrograph and Soft Imaging Viewer Software.
Particle size distribution and zeta potential
The particle size and zeta potential analyses of all NPs were performed 
by photon correlation spectroscopy (PCS) and laser diffractometry (LD). 
For PCS measurements, 1 mL of the NPs solution was filled in the 
disposable transparent sizing clear cuvette, and the size of the sample 
was analyzed at 25°C with a Malvern Zetasizer (Malvern Instruments, 
Westborough, Massachusetts). All measurements were performed in 
triplicate.
Fourier transform infrared spectroscopy (FTIR)
FTIR spectra of PEG-amine, HP, PLL, MES, NVNPs, AVNPs, CRNPs, and 
AV-CRNPs were determined using Bruker Vector 22 FTIR. The spectra 
were obtained in the range of 500–4000 cm−1.
In vivo application
Animals
A total of 114 (n=114) male Albino rats of Wistar strain 
(body weight 100–120 g) were used in this study. Animals will be 
obtained from the Animal House Colony at National Research Centre, 
Giza, Egypt. The animals were housed in a specific pathogen-free barrier 
area in a room with controlled temperature (22±1°C) and humidity 
(50±10%) and a 12 h light/dark cycle. The rats were allowed ad libitum 
access to water and standard laboratory diet consisting of casein 10%, 
salts mixture 4%, vitamins mixture 1%, corn oil 10%, and cellulose 5% 
completed to 100 g with cornstarch [25]. The study protocol followed 
the guidelines approved by the Ethical Committee of the Medical 
Research of the National Research Centre (Approval No. 16/281).
Experimental design
A total of 114 males (n=114) of  Wistar rats were used in the current 
study and divided into 7 groups. All groups were treated daily for 
30 days with vehicle (Group 1, control, n=6),  AV (Group 2, n=18),  AVNP 
(Group 3, n=18), CR (Group 4, n=18), CRNP (Group 5, n=18), AVCR 
(Group 6, n=18), and AVCRNP (Group 7, n=18). Groups (2-7) were 
subdivided into three subgroups (n=6 in each subgroup) according to the 
administrated dose (high safe dose, D1; half safe dose, D2; and quarter 
safe dose, D3). These doses (showed in Table 1) were administrated orally 
and determined according to a preliminary study that was performed 
about acute and chronic toxicity of these nano-formulations in vivo.
Blood sampling and biochemical investigations
At the end of the experimental period, rats were fasted overnight 
and subjected to diethyl ether anesthesia. Blood samples were 
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immediately collected from the retro-orbital venous plexus and 
divided into two portions, the first portion was collected using 
vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) 
(BD Company, Canada) for differential leukocytes and platelets, while 
the second portion was be left to clot in clean, dry test tubes, and then 
centrifuged at ×1800 g for 10 min to obtain sera. The clear supernatant 
sera were used for VEGF concentration measurements.
From sampling to differential leukocytes and platelets measurement
Medonic M32 analyzer included MPA micro-pipette adapter for sampling 
(Boule Diagnostics AB Company, Sweden) was used for complete blood 
count (CBC) of rat blood samples which collected using vacutainer 
tubes containing EDTA (BD Company, Canada). 20 µL of blood samples 
were collected from the vacutainer tubes and simply drawn into the 
micro-capillary tube connected with the MPA micro-pipette adapter 
for CBC analysis. Medonic M32 analyzer comes equipped with a 
high-precision shear-valve for getting accurate results of hematology 
analysis. Hematological analysis is concerned with the analysis of the 
cellular component of blood including tests that used for evaluation of 
erythrocyte, leukocyte, and platelet pictures. Different parameters were 
analyzed as follow: Total white blood cells (WBC), differential leukocyte 
count (lymphocytes percentage, monocytes percentage, and granulocytes 
percentage), platelet count (PLT), the amount of blood occupied by 
platelets (platelet crit; PCT), the average volume of platelet (mean platelet 
volume [MPV]), the variation in size of platelets in the blood circulation 
(platelets distribution width [PDW]), and the concentration of the LP in 
the blood circulation (LP concentration ratio [LPCR]).
VEGF level measurement using ELISA
Rat VEGF ELISA Kit (Cat. No. E-EL-R0020, Elabscience Biotechnology 
Co., USA) was used for quantitative determination of rat VEGF 
concentrations in rat sera after the different treatments compared 
to control. The principle of this kit is based on the sandwich-ELISA 
method. Briefly, we have drawn a standard curve using the provided 
VEGF standard. The standard working solution was prepared by 
centrifuging the standard at ×10,000 g for 1 min. Then, 1 mL of the 
provided reference standard and sample diluent was added and left 
for 10 min by mixing gently. The reconstitution produced a working 
solution of 2000 pg/mL, then we made serial dilutions as follows: 2000, 
1000, 500, 250, 125, 62.5, 31.25, and 0 pg/mL. We started the procedure 
with adding 100 µL of the prepared standard or sample to each well, 
then they were incubated for 90 min at 37°C, thereafter the liquid was 
removed. We diluted the biotinylated detection Ab (1: 100) and left it 
for 15 min earlier before adding 100 µL of it to each well; then the plate 
was incubated for 1 h at 37°C. The plate was aspirated and washed for 
3 times. We diluted the concentrated horseradish peroxidase (HRP) 
conjugate (1: 100) and left it for 15 min earlier before adding 100 µL 
of HRP conjugate to each well; then the plate was incubated for 30 min 
at 37°C. The plate was aspirated and washed for 3 times. 50 µL of the 
provided substrate reagent was added and incubated for 15 min at 37°C. 
The reaction in each well was stopped before reading by 50 µL of stop 
solution, then the OD value at 450 nm was determined immediately. The 
OD is proportional to the concentration of rat VEGF. The concentration 
of rat VEGF was calculated in the samples by comparing the OD of the 
samples to the diagrammed standard curve.
From tissue sampling to histopathological investigation
Autopsy samples were taken from the liver of rats in the different 
groups and fixed in 10% formol saline for 24 h. Washing of 
samples was done in tap water then serial dilutions of alcohol 
(methyl, ethyl, and absolute ethyl) were used for dehydration. 
Specimens were cleared in xylene and embedded in paraffin at 56°C in 
hot air oven for 24 h. Paraffin bees wax tissue blocks were prepared for 
sectioning at 4 microns thickness by sledge microtome. The obtained 
tissue sections were collected on glass slides, deparaffinized, and 
stained by hematoxylin and eosin stains for examination through the 




For measuring the EE of AV in the nano-capsules (AVNPs and AV-CRNPs), 
calibration curve of AV after dialysis tubing was performed. The serial 
dilutions used for drawing the calibration curve are 0.39, 0.78, 1.56, and 
3.12 mg/mL as shown in Fig. 1. The EE of AV in AV NPs was 86±5.5 and 
in AV-CRNPs was 82±7.0.
For measuring the EE of CCR2 antagonist (CR) in the nano-capsules 
(CRNPs and AV-CRNPs), calibration curve after dialysis tubing was 
performed. The serial dilutions used for drawing the calibration curve 
are 0.0078, 0.0156, 0.0312, 0.0625, and 0.125 mg/mL as shown in Fig. 1. 
The EE of CR in CR NPs was 74 ± 2.8 and in AV-CR NPs was 75 ± 6.4.
TEM
TEM was used for imaging of PEG-based NPs as illustrated in Fig. 2. 
The morphology of the NV is spherical in shape as illustrated in Fig. 2a. 
In addition, these spherical NVNPs have sizes ranging from 89.89 nm 
to 99.06 nm as illustrated in Fig. 2b. In Fig. 2c, high scale field (1 µm) 
of AV NPs morphology shows spherical core particles surrounded 
by monoclonal AV antibody. Sizes of AV NPs were in the range of 
145-146 nm. In Fig. 2d, high scale field (500 nm) of CRNPs morphology 
shows that spherical particles were illustrated. Sizes of CRNPs were in 
the range of 57.7–73.36 nm.
Fig. 2e shows TEM images of AVCR NPs. It illustrates high scale field 
(500 nm) of AV-CRNPs morphology shows spherical core particles 
surrounded by monoclonal AV antibody. Sizes of AVNPs were in the 
range of 139–155.65 nm.
Size and zeta potential stability of NPs
As shown in Fig. 3, size distribution and apparent zeta potential of the 
NPs were characterized. Representative size distribution (108.9 nm) of 
NV was drawn using Malvern ZetaSizer system based on PCS and LD as 
illustrated in Fig. 3a. In addition, representative zeta potential (4.99 mV) 
of NV was distributed using Malvern Zetasizer system based on PCS and 
LD as illustrated in Fig. 3b. Representative size distribution (147.8 nm) of 
AVNPs was drawn in Fig. 3c. Representative zeta potential (−9.05 mV) of 
AVNPs was drawn in Fig. 3d. Representative size distribution (76.26 nm) 
of CR NPs was drawn in Fig. 3e. Representative zeta potential (−2.81 mV) 
of AVNPs was drawn in Fig. 3f. Representative size distribution (293.4 nm) 
of AV-CRNPs was drawn in Fig. 3g. Representative zeta potential 
(4.71 mV) of AV-CRNPs was drawn in Fig. 3h.
FTIR spectroscopy
Schematic diagram (Fig. 4) of NPs was illustrated to figure the vehicle 
components that incorporated in the nano-encapsulation of all 
particles. To prepare PEG NPs, we first prepared the mixture of EDC and 
NHS. Then, NPs were produced simply by mixing the polymer with PLL 
buffer overnight at 4°C with the mix ratio (1:6 v/v, PLL: PEG-HP). NV, AV 
NPs, CR NPs, and AV-CR NPs encapsulation is accompanied with peptide 
bond “O=C-NH” formation.
Fig. 5a shows the Fourier Transform infrared spectroscopy (FTIR) 
of PEG-amine, heparin (HP), poly L-lysine (PLL), MES, and NV NPs 
Table 1: The doses of the administrated therapeutic regimens
Groups Mg/kg
High safe dose, 
D1
Half safe dose, 
D2
Quarter safe dose, 
D3
AV 5 2.5 1.25 
AVNP 5 2.5 1.25 
CR 0.001 0.0005 0.00025
CRNP 0.001 0.0005 0.00025
AVCR 5+0.001 2.5+0.0005 1.25+0.00025
AVCRNP 5+0.001 2.5+0.0005 1.25+0.00025
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which were determined using Bruker Vector 22 FTIR. The spectra 
were obtained in the range of 500–4000 cm−1. NV encapsulation is 
accompanied with amide bond “O=C-NH” formation. On the other hand, 
Fig. 5b shows the FTIR of HP and PLL which were magnified to increase 
clarity. Moreover, FTIR of NV NPs, AV, and AV NPs were determined 
using Bruker Vector 22 FTIR Fig. 6a.  The spectra were obtained in the 
range of 500–4000 cm-1. NV encapsulation is accompanied with peptide 
bond “O=C-NH” formation. Fig. 6b illustrates the FTIR of NVNPs, AV, CR, 
CRNPs, and AV-CRNPs which were determined. Fig. 6c illustrates the 
FTIR of AV and CR which were magnified to increase clarity
Immunomodulation: Immune cells, platelets, and VEGF network
AV, AVNP, CR, CRNP, AVCR, and AVCRNP played a crucial role in 
immunomodulation after their administration in vivo rats. In Fig. 7a, 
monocytes were high significantly (p<0.01) elevated in blood after 
treatments with AV, AVNP, CR, CRNP, AVCR, and AVCRNP. This elevation 
of monocytes led to an accumulation of these immune cells in the 
circulatory system. This elevation of monocytes led to an accumulation 
of these immune cells in the circulatory system. We noticed that there 
was a significant dose-dependent increase (p<0.05) only in the nano-
formulated regimens of AV, CR, and AVCR, while there was no stable 
pattern in the case of the free regimens of AV, CR, and AVCR. In addition, 
lymphocytes were significantly (p<0.05) elevated in blood after 
treatments with AV, AVNP, CR, CRNP, AVCR, and AVCRNP as shown in 
Fig. 7b. This elevation of lymphocytes led to an accumulation of these 
immune cells in the circulatory system. We noticed that there was a 
significant dose-dependent increase (p<0.05) of lymphocytes only in the 
individual regimens including AV, AVNP, CR, and CRNP, while there was a 
significant dose-dependent decrease (p<0.05) only in the combinatorial 
regimens including AVCR and AVCRNP. However, 0.0005 mg/kg of CRNP 
(the quarter dose) induced the elevation of lymphocytes more than 
0.00025 mg/kg of CRNP (the half dose), we observed a strange pattern 
in the case of CRNP, where the lymphocytes after the high dose of CRNP 
(0.001 mg/kg) administration was significantly decreased (p<0.001) 
compared to the half and the quarter doses and even the control. 
Furthermore, there were total leukocyte (WBCs) and granulocyte 
patterns of dose-dependent decreases (p<0.05) after treatments with 
AV, AVNP, CR, CRNP, AVCR, and AVCRNP as shown in Table 2.
Fig. 7c and d showed the hemostatic balance between platelets and 
the LP (the LPCR), where the platelets were decreased significantly 
(p<0.05) in blood (Fig. 7c), while the LPCR was elevated in the blood 
circulation (Fig. 7d). Table 3 showed that there were no dramatically 
changes of MPV, PDW, and PCT levels in the blood circulation when 
comparing the treated groups of the administrated therapeutic 
regimens with the control.
Fig. 7e illustrated that VEGF levels in rat sera were significantly 
decreased (p<0.01) when comparing the treated groups with the 
control. We noticed that there was a significant dose-dependent 
increase (p<0.05) of VEGF levels only in the individual regimens 
including AV, AVNP, CR, and CRNP, while there was a significant dose-
dependent decrease (p<0.05) only in the combinatorial regimens 
including AVCR and AVCRNP.
Fig. 1: Calibration curves of Avastin (AV) and CCR2 antagonist (CR) used for measuring entrapment efficiency of AV nanoparticles (NPs), 
CRNPs, and AV-CRNPs
Fig. 2: Transmission electron microscopic analyses. (a) NV 
morphology was spherical in shape. (b) Sizes of spherical NV 
nanoparticles (NPs) were 89.89 nm and 99.06 nm. (c) AVNPs 
morphology shows spherical core particles surrounded by 
monoclonal AV antibody. Sizes of AVNPs were in the range of 
145–146 nm. (d) CRNPs morphology shows spherical particles. 
Sizes of CRNPs were in the range of 57.7–73.36 nm. (e) AV-CRNPs 
morphology shows spherical core particles surrounded by 
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Fig. 4: Schematic diagram of nanoparticles encapsulation. To prepare PEG-HP- poly L-lysine (PLL) NPs, we first prepared the mixture of 
EDC and NHS. Then, NPs were produced by mixing the polymer with PLL phosphate buffer overnight at 4°C. The mix ratio (1:6 v/v, PLL: 
PEG-HP). NV, AVNPs, CRNPs, and AV-CRNPs encapsulation is accompanied with peptide bond “O=C-NH” formation
Histopathological alterations
The obtained tissue sections taken from the rat liver were stained by 
hematoxylin and eosin stains for investigation through the light electric 
microscope. Histopathological alterations were shown in Fig. 8. In control 
liver, there was no histopathological change, and the normal histological 
structure of the central vein and hepatocytes in the parenchyma were 
Fig. 3: Size distribution and apparent zeta potential. (a) Representative size distribution (108.9 nm) of NV (F1) was drawn using Malvern 
ZetaSizer system based on PCS and laser diffractometry (LD). (b) Representative zeta potential (4.99 mV) of NV (F1) was drawn using 
Malvern ZetaSizer system based on PCS and LD. (c) Representative size distribution (147.8 nm) of AV nanoparticles (NPs) was drawn. 
(d) Representative zeta potential (−9.05 mV) of AVNPs was drawn. (e) Representative size distribution (76.26 nm) of CRNPs was drawn. 
(f) Representative zeta potential (−2.81 mV) of AV NPs was drawn. (g) Representative size distribution (293.4 nm) of AV-CRNPs was 
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recorded as shown in Fig. 8a. After AV administration with the high 
dose, the parenchyma showed focal necrosis with inflammatory cells 
infiltration associated with congestion in the central vein as well as 
the portal vein as shown in Fig. 8b. After AV administration with the 
quarter dose, focal necrosis with inflammatory cells infiltration was 
detected in the parenchyma associated with edema and inflammatory 
cells infiltration in the portal area as shown in Fig. 8c. After AVNP 
administration with the high dose, the portal area showed inflammatory 
cells infiltration, while the parenchyma had focal necrosis as shown in 
Fig. 8d. After AVNP administration with the quarter dose, the parenchyma 
showed focal necrosis associated with inflammatory cells infiltration in 
the portal area as shown in Fig. 8e. After CR administration with the high 
dose, massive inflammatory cells infiltration was detected in the portal 
area as shown in Fig. 8f. After CR administration with the quarter dose, 
the portal area showed focal inflammatory cells aggregation as well as 
diffuses inflammatory cells infiltration in the others with congestion in 
the portal vein as shown in Fig. 8g. After CRNP administration with the 
high dose, periductal fibrosis with inflammatory cells infiltration was 
detected surrounding the bile ducts at the portal area with congestion 
in the portal vein as shown in Fig. 8h. After CRNP administration 
with the quarter dose, the portal area showed massive inflammatory 
cells infiltration as well as focal inflammatory cells aggregation in the 
parenchyma as shown in Fig. 8i. After AVCRNP administration with the 
high dose, massive inflammatory cells infiltration was detected in the 
portal area as shown in Fig. 8j.
Leukocyte migration process involves multi-steps and regulates the 
presence of immune cells throughout the human being’s body. In 
normal noninflammatory circumstances, homeostatic chemokines are 
supposed to adjust the transmission of hematopoietic cells intermediate 
- between blood and tissues. Inflammation induces changes in the 
cellular compositions of these sites, with quicker infiltration of immune 
cells from the bone marrow to the circulation [27].
The infiltration of the circulating immune cells into tissues is supposed to 
be driven by connections between chemokine receptors (example: CCR2) 
Fig. 5: (a) Fourier transform infrared spectroscopy (FTIR) of PEG-amine, heparin (HP), poly L-lysine (PLL), MES, and NVNPs was 
determined using Bruker Vector 22 FTIR. The spectra were obtained in the range of 500–4000 cm−1. NV encapsulation is accompanied 
with peptide bond “O=C-NH” formation and (b) the FTIR of HP and PLL were magnified to increase clarity
a b
Fig. 6: (a) Fourier transform infrared spectroscopy (FTIR) of NVNPs, AV, and AVNPs was determined using Bruker Vector 22 FTIR. The 
spectra were obtained in the range of 500–4000 cm−1. NV encapsulation is accompanied with peptide bond “O=C-NH” formation. (b) The 
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Fig. 7: The mechanism of the action of immunomodulation after AV, AVNP, CR, CRNP, AVCR, and AVCRNP administrations in vivo. 
Monocytes (a) and lymphocytes (b) were significantly accumulated in blood after treatments with AV, AVNP, CR, CRNP, AVCR, and AVCRNP. 
Platelets were decreased in blood (c), while the LP (the LPCR) was elevated in the blood circulation (d). (e) VEGF levels in rat sera were 
significantly decreased when comparing the treated groups with the control. (f and g) Schematic diagrams of the mechanism of action of 
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and their ligands (example: CCL2) [28]. CCR2 has been allied with the 
recruitment of monocytes and/or lymphocytes from the circulation to 
the target sites [29,30]. Herein, we have examined the effect of CCR2 
antagonist on monocyte and lymphocytes relocation. Our results have 
designated that CCR2–CCR2 antagonist interactions were blocked the 
infiltration of monocytes from the blood, resulting in an accumulation 
of these types of immune cells in the circulation, as we observed in 
the results (Fig. 7g). This observation is in agreement with a previous 
study [31]. For more clarification of that point, it was validated that the 
lack of CCR2 changed the shape of circulating monocytes recommending 
that reduced inflammation may consequence from diminished 
inflammatory monocyte rates in the circulation rather than from reduced 
staffing of monocytes from the circulation into tissues [31]. Monocyte 
relocation from the circulation to the organ and succeeding relocation 
toward T cell parts of the white pulp might encompass the consecutive 
arrangement of numerous chemokines separate from CCR2 [32,33].
Basically, CCL2 is secreted in response to inflammation [34]. In 
normal conditions, low secretion of CCL2 induces the homeostatic 
relocation of inflammatory monocytes from bone marrow into the 
bloodstream [31]. For example, infection with Listeria monocytogenes 
persuades CCL2 secretion in the spleen and the blood circulation [35].
A considerable number of clinical surveys emphasized that inflammation 
contributes greatly in tumor formation [36]. The crosstalk between 
tumor cells and the tumor-infiltrating cells is also shown recently as 
a significant contributor in cancer development, drug resistance, and 
cancer invasion. For example, CCL2, secreted by numerous tumors, 
mediates immunoinhibitory effects and facilitates tumor metastasis. 
Blocking of CCL2-CCR2 signaling using CCR2 antagonist, as studied 
here in the current study, can be further used to boost CD8+ T-cell-
mediated responses and inhibit metastasis [37].
However, even though angiogenesis is the communal leading cause of tumor 
progression, abruptly targeting the crucial contributing factor, VEGF, is still 
risky. Based on the assumption that tumor mass consists of multigenotypic 
population, the VEGF-targeting therapy (i.e. AV) may select for the adapting 
tumor cells [38]. According to previous results from human cancer studies, 
anti-VEGF therapy usually results in regrowth of clonal populations with 
the characteristics of expressing higher compensatory factors such as 
VEGF, fibroblast growth factor, and platelet-derived growth factor [38], so 
we used AV in combination with CCR2 antagonist (CR) to inhibit VEGF and 
block the CCR2-CCL2 signaling network that may be used as a promising 
anticancer therapeutic regimen in further studies.
It was suggested that nano-formulation of chemotherapies increases 
their targetability and stability in addition to reduces adverse effects of 
them and provides adequate drug delivery approach [18-21]. Recently, 
several delivery systems were developed by utilizing pegylation 
process [39], which increased the half-life and activity of drugs, 
and reduced liver toxicity in mice, thus allowing the drug dosages 
to be reduced [40]. NPs have been great predestined as carriers for 
the delivery of drugs due to their small size, and sustained-release 
characteristics [41,42].
In the current study, we used PEG and PLL for synthesizing the AV, 
CR, and AV-CR NPs. PLL has a benefit of being hydrodegradable, 
biodegradable, and biocompatible [43], and so it is appropriate for the 
backbone as a drug delivery transporter. Recently, it has been reported 
that PLL-modified poly (lactic-co-glycolic acid) (PLGA) NPs presented 
significantly higher quantities than unmodified PLGA NPs [44]. 
Therefore, in this work, we selected PLL and PEG for encapsulating AV 
and CCR2 antagonist (CR) to achieve bioavailable and biocompatible 
NPs, as well as the sustained release of these drugs.
Our AV PEG-PLL NPs noted high encapsulation efficiency (EE =86%) 
of AV with high stability based on the zeta potential negative charges 
(−9.05+1.2)  reported  on  the  surface  of  the  synthesized  AVNPs,  then 
TEM images came to confirm its uniformity and z-average diameter 
came to confirm that it is in the nano-range (147.8+3.4) and PDI of 0.01. 
On the contrary, the authors in a previous study [45] found that a higher 
loading of AV, the PLGA particles lost its uniform, this was most likely 
due to fractional phase parting of PLGA polymer and AV.
When authors added PEG to their NPs (PEG-PLGA), it is supposed that 
the NPs produced from this polymer are long-circulating within the 
in vivo model, because PEG is widely used as a graft-forming polymer 
in addition to the release rate of the loaded therapeutic molecule. 
Table 2: WBCs and granulocytes measurements after the dose-dependent manner of the administrated therapeutic regimens
Parameters Groups CT D1 D2 D3
Mean±SD Mean±SD Mean±SD Mean±SD
WBCs AV 11.8±1.01 7.4±0.62 9±0.75 6.3±0.57
AVNP 11.8±1.01 8.8±0.73 11.4±0.95 5.7±0.52
CR 11.8±1.01 9.5±0.79 11.2±0.93 11.3±1.03
CRNP 11.8±1.01 6.9±0.58 14.2±1.18 23.5±2.14
AVCR 11.8±1.01 7.6±0.63 11.4±0.95 13.0±1.18
AVCRNP 11.8±1.01 8.8±0.73 7.8±0.65 10.6±0.96
Granulocytes (%) AV 33.1±2.83 16.3±1.36 19.5±1.63 11.7±1.06
AVNP 33.1±2.83 17.8±1.48 17.4±1.45 16.3±1.48
CR 33.1±2.83 20.8±1.73 21.3±1.78 10.8±0.98
CRNP 33.1±2.83 20±1.67 26.8±2.23 57.2±5.20
AVCR 33.1±2.83 11.4±0.95 15.5±1.29 40.3±3.66
AVCRNP 33.1±2.83 15.4±1.28 15.6±1.30 20.7±1.88
Table 3: MPV, PDW, and PCT measurements after the 
dose-dependent manner of the administrated therapeutic 
regimens
Parameters Groups CT D1 D2 D3
Mean±SD Mean±SD Mean±SD Mean±SD
MPV AV 5.7±0.49 6.1±0.51 5.6±0.47 5.9±0.54
AVNP 5.7±0.49 5.7±0.48 6.5±0.54 6.6±0.60
CR 5.7±0.49 6.8±0.57 6.5±0.54 6.6±0.60
CRNP 5.7±0.49 5.7±0.48 5.5±0.46 6±0.55
AVCR 5.7±0.49 6.3±0.53 6.1±0.51 6.1±0.55
AVCRNP 5.7±0.49 6.7±0.56 6.3±0.53 6.3±0.57
PDW AV 8.8±0.75 6.2±0.52 8.6±0.72 9.1±0.83
AVNP 8.8±0.75 8.8±0.73 9.8±0.82 9.9±0.90
CR 8.8±0.75 10±0.83 9.8±0.82 9.9±0.90
CRNP 8.8±0.75 8.7±0.73 8.6±0.72 9.1±0.83
AVCR 8.8±0.75 9.4±0.78 9.3±0.78 9.2±0.84
AVCRNP 8.8±0.75 9.9±0.83 9.4±0.78 9.5±0.86
PCT AV 0.54±0.05 0.38±0.03 0.34±0.03 0.23±0.02
AVNP 0.54±0.05 0.34±0.03 0.42±0.04 0.42±0.04
CR 0.54±0.05 0.62±0.05 0.28±0.02 0.37±0.03
CRNP 0.54±0.05 0.21±0.02 0.42±0.04 0.53±0.05
AVCR 0.54±0.05 0.31±0.03 0.39±0.03 0.30±0.03
AVCRNP 0.54±0.05 0.54±0.05 0.60±0.05 0.63±0.06
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Unlike PLGA, the hydrophilicity of PEG also facilitated dispensing the 
particles [45]. These results are in agreement of our PEG-PLL based NPs.
It is suggested that the use of liposomes was stated for augmenting the 
in vivo residence of AV in in vivo model [46]. However, the described 
drug EE was only about 45%. Hao et al. [47] also conveyed a similar 
drug EE using ethyl acetate and phosphate solution. However, in our 
method, the EE of the AV PEG-PLL NPs recorded (86%), which is a bit 
similar to Li’s PLGA-PEG drug EE (90%), which was achieved through 
double emulsion method [45].
The problem of AV PLGA NPs is that after a certain time period, the 
PLGA instigated degrading and released additional drug entrapped in 
the polymeric base [48], so it is not stable such as our synthesized AV 
PEG-PLL NPs.
In a previous study, PEG-grafted chitosan NPs were synthesized [49]. 
As FTIR technique was investigated in the current study, they also 
performed the same techniques and indicated that the nonexistence of 
peaks at 1774 cm−1 and 1710 cm−1 in their NPs confirm the complete 
dissociation of phthalimido group from chitosan and the entrance of 
peaks 1633 cm−1 (amide I) and 1582 cm−1 (amide II) corresponds to the 
attendance of primary amine groups in chitosan. The peak at 2871 cm−1 
refers to the attendance of PEG, which a little bit similar to our FTIR 
results.
CCL2 was proved to recruit the monocytes into the area of dynamic 
inflammation. In this term, it was found that the inspiration of 
RANTES leads to staffing of monocytes/lymphocytes [50,51]. Apart 
from employing leukocyte movement, many lines of signals indicate 
that CCL2 might affect T-immunity. First, CCL2 upregulation is linked 
with the progress of polarized Th2 responses [52], and CCL2 improves 
the emission of IL-4 by T cells [53]. Second, in Th2 immune-mediated 
diseases, such as asthma, CCL2 is expressed at high levels, and its 
neutralization in animal models ameliorates disease [54]. Finally, 
other chemokines and their receptors are linked to specific responses 
of T-helper cells [55]. These findings provide an important clue in the 
current study as to why when we blocked the CCR2-CCL2 signaling 
pathway the monocytes and lymphocytes were not infiltrated and then 
accumulated in the circulation.
This may be critical for the effective directive of the immune reply to 
cancer and viral infection for further studies. For example, Th1 and 
Th2 cells, due to their dissimilar chemokine receptor expression design 
induced by CCL2, are likely to have dissimilar susceptibility to viral 
infection [53].
Chemokines are elaborate in normal activities in the host that affect 
tumor; hence, it is probable that they will be existing to have important 
impacts on different cancers. For this reason, chemokines might be 
predictable to have growth regulating effects on cancer cells depending 
on the specific setting in which they are found. Further, due to their 
ability to attract lymphocytes, some chemokines might be predicted to 
activate host antitumor replies. On the other hand, certain chemokines 
are known to have angiogenic properties, which could relate to tumor 
progression [56]. CCL2 expression in tumor cells is significantly 
connected with the extent of tumor-associated-macrophage (TAM) 
penetration [57], and in particular, both CCL2 and VEGF expressions 
were positively linked with TAM infiltration, angiogenesis, and then 
poor cancer survival [58].
The observations presented in a previous study [59] indicated that 
activated platelet interactions with the monocytes promote the 
inducible form of cyclooxygenase (COX-2) expression and augmented 
prostaglandin E2 (PGE2) synthesis by monocytes by methods 
concerning cellular adhesion and in response induced cytokine 
pathways. Rapid binding of P-select in on the plasma membranes of 
triggered platelets to the monocytes mediates stable communication 
between the 2 cell types [60]. Moreover, monocytes adhesion to 
P-select modulates the protein and gene expression of COX-2. A similar 
design was described for some transcripts in models of monocyte 
gene expression induced by adhesion to matrix structures by surface 
integrins [61]. A second signal is then delivered by IL-1β in response to 
the cellular communication. Thus, regulation of COX-2 expression may 
exist at both transcriptional and post-transcriptional levels, consisting 
with the COX-2 enzyme as a highly regulated gene [62]. Unregulation of 
COX-2 may affect inflammatory response together with interpretations 
that platelet activation and platelet-leukocyte aggregation are 
frequently linked with these ailments [63-66].
Integrative pathways of COX-2 protein synthesis are associated with 
monocytes response to different signals and related to activated 
platelets which regulate through COX-2 gene in a specialized cellular 
process. This way of control may evolve for a controlled inflammatory 
response and here we can discuss the results summarized in Fig. 7f 
and g, when we blocked the CCR2 expressed on the immune cells 
(example: Monocytes) using the CCR2 antagonist (CR) in their free and 
Fig. 8: Histopathological alteration. (a) Control liver, 
(b) liver after AV administration with the high dose, (c) 
liver after AV administration with the quarter dose, (d) 
liver after AVNP administration with the high dose, (e) liver 
after AVNP administration with the quarter dose, (f) liver 
after CR administration with the high dose, (g) liver after 
CR administration with the quarter dose, (h) liver after 
CRNP administration with the high dose, (i) liver after CRNP 
administration with the quarter dose, and (j) liver after AVCRNP 
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nanoformulations that lead to lowering of immune cell infiltration from 
the circulation. Providing AV to CR in their free and nanoformulations 
significantly inhibited VEGF. Eventually, the accumulation of monocytes 
in the circulating blood leads to platelet (PLT)-monocyte interaction 
with the aggregation of the PLT in the form of LPCR (Fig. 7g).
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